Hyep Ivan reported option exercise involving 9,200 derivative units of Bicara Therapeutics Inc. at $0.00 for $0 on May 21, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Financial Officer
Chief Financial Officer
Filed May 26, 2026

Facts from the filing

Form 4 · Derivative, table II
Disclosed value
$0Shares × reported price
Shares traded
9,200Stock Option (Right to Buy)
Price per share
$0.00Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
70,584Direct
Trade date
May 21, 2026Option exercise
Filed
May 26, 2026, 5:48 PM ET5-day reporting delay
Accession
0001628280-26-038248Code M · Transaction 385979
How reported position traded is calculated

Not calculated for derivative securities.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 21, 2026Sell9,200$20.42−$187,883.32Trade 385978
May 21, 2026Option exercise9,200$3.79$34,866.16Trade 385977
3 transaction rows in this filing. Joint filers share the same rows.

BCAX price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
BCAX · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago +5.1%1w ago −6.1%1d ago −7.1%
Returns since7d −11%30d +20%90d +7.3%180d1y

Footnotes in full

F1: This transaction was executed pursuant to a Rule 10b5-1 trading plan adopted on February 13, 2025. F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $20.25 to $20.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. F3: The shares underlying this option vest in sixteen equal quarterly installments following August 8, 2023, subject to the Reporting Person's continued service on each such vesting date.